Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters











Database
Language
Publication year range
1.
Gynecol Oncol ; 156(1): 77-84, 2020 01.
Article in English | MEDLINE | ID: mdl-31796203

ABSTRACT

OBJECTIVE: Determine the utility of a clinical calculator to predict the benefit of chemotherapy in stage IA uterine papillary serous cancer (UPSC). PATIENTS AND METHODS: Data were collected from NCDB from years 2010-2014. Based on demographic and surgical characteristics, a clinical score was developed using the random survival forest machine learning algorithm. RESULTS: Of 1,751 patients with stage IA UPSC, 1,012 (58%) received chemotherapy and 739 (42%) did not. Older age (HR 1.06), comorbidities (HR 1.31), larger tumor size (HR 1.27), lymphovascular invasion (HR 1.86), positive peritoneal cytology (HR 2.62), no pelvic lymph node dissection (HR 1.51), and no chemotherapy (HR 2.16) were associated with poorer prognosis. Compared to no chemotherapy, patients who underwent chemotherapy had a 5-year overall survival of 80% vs. 67%. To better delineate those who may derive more benefit from chemotherapy, we designed a clinical calculator capable of dividing patients into low, moderate, and high-risk groups with associated 5-year OS of 86%, 73%, and 53%, respectively. Using the calculator to assess the relative benefit of chemotherapy in each risk group, chemotherapy improved the 5-year OS in the high (42% to 64%; p < 0.001) and moderate risk group (66% to 79%; p < 0.001) but did not benefit the low risk group (84% to 87%; p = 0.29). CONCLUSION: Our results suggest a clinical calculator is useful for counseling and personalizing chemotherapy for stage IA UPSC.


Subject(s)
Algorithms , Cystadenocarcinoma, Papillary/drug therapy , Cystadenocarcinoma, Serous/drug therapy , Machine Learning , Uterine Neoplasms/drug therapy , Aged , Cystadenocarcinoma, Papillary/pathology , Cystadenocarcinoma, Papillary/surgery , Cystadenocarcinoma, Serous/pathology , Cystadenocarcinoma, Serous/surgery , Female , Humans , Neoplasm Staging , Nomograms , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Reproducibility of Results , Uterine Neoplasms/pathology , Uterine Neoplasms/surgery
2.
Gynecol Oncol ; 148(2): 275-280, 2018 02.
Article in English | MEDLINE | ID: mdl-29195926

ABSTRACT

OBJECTIVE: To identify clinicopathologic factors associated with 10-year overall survival in epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC), and to develop a predictive model identifying long-term survivors. METHODS: Demographic, surgical, and clinicopathologic data were abstracted from GOG 182 records. The association between clinical variables and long-term survival (LTS) (>10years) was assessed using multivariable regression analysis. Bootstrap methods were used to develop predictive models from known prognostic clinical factors and predictive accuracy was quantified using optimism-adjusted area under the receiver operating characteristic curve (AUC). RESULTS: The analysis dataset included 3010 evaluable patients, of whom 195 survived greater than ten years. These patients were more likely to have better performance status, endometrioid histology, stage III (rather than stage IV) disease, absence of ascites, less extensive preoperative disease distribution, microscopic disease residual following cyoreduction (R0), and decreased complexity of surgery (p<0.01). Multivariable regression analysis revealed that lower CA-125 levels, absence of ascites, stage, and R0 were significant independent predictors of LTS. A predictive model created using these variables had an AUC=0.729, which outperformed any of the individual predictors. CONCLUSIONS: The absence of ascites, a low CA-125, stage, and R0 at the time of cytoreduction are factors associated with LTS when controlling for other confounders. An extensively annotated clinicopathologic prediction model for LTS fell short of clinical utility suggesting that prognostic molecular profiles are needed to better predict which patients are likely to be long-term survivors.


Subject(s)
Neoplasms, Glandular and Epithelial/mortality , Ovarian Neoplasms/mortality , Peritoneal Neoplasms/mortality , Aged , Ascites/mortality , Ascites/pathology , CA-125 Antigen/metabolism , Carcinoma, Ovarian Epithelial , Female , Humans , Middle Aged , Neoplasm, Residual , Neoplasms, Glandular and Epithelial/pathology , Ovarian Neoplasms/pathology , Peritoneal Neoplasms/pathology , ROC Curve , United States/epidemiology
3.
J Neonatal Perinatal Med ; 9(3): 325-31, 2016 Sep 16.
Article in English | MEDLINE | ID: mdl-27589544

ABSTRACT

Uterine artery embolization (UAE) is typically not indicated in the pre-operative management of pregnancies with a live fetus, because risk of fetal death from reduced uteroplacental blood flow. However, pre-operative UAE in pregnancies with a fetal demise poses no fetal risk, and may offer maternal benefits. Patients with placental abruption resulting in fetal demise are at high-risk for developing disseminated intravascular coagulation (DIC), which could have devastating complications such as peri-operative hemorrhage and death. This case report describes the first successful execution of a pre-operative UAE that effectively prevented antepartum and postpartum hemorrhage in a patient with DIC secondary to a placental abruption and recent fetal demise.


Subject(s)
Abruptio Placentae/diagnostic imaging , Blood Transfusion/methods , Disseminated Intravascular Coagulation/diagnostic imaging , Fetal Death , Pregnancy Complications/diagnostic imaging , Uterine Artery Embolization , Abdominal Pain , Abruptio Placentae/therapy , Adult , Disseminated Intravascular Coagulation/complications , Disseminated Intravascular Coagulation/therapy , Female , Humans , Pregnancy , Pregnancy Complications/therapy , Treatment Outcome , Uterine Artery Embolization/methods
SELECTION OF CITATIONS
SEARCH DETAIL